International Stem Cell (ISCO) Assets Average (2011 - 2026)
International Stem Cell (ISCO) posted quarterly Assets Average of $5.1 million for Q4 2025, down 2.43% year-over-year from $5.2 million in Q4 2024, and down 6.72% quarter-over-quarter from $5.4 million in Q3 2025.
International Stem Cell (ISCO) Assets Average (2011 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Assets Average for 15 consecutive years, with $5.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average fell 2.43% year-over-year to $5.1 million; the TTM figure through Dec 2025 stood at $5.1 million (down 2.43% YoY), while the FY2025 annual figure was $5.0 million, down 5.41% from the prior year.
- Assets Average declined to $5.1 million in Q4 2025 per ISCO's latest filing, from $5.4 million in the prior quarter.
- Across five years, Assets Average topped out at $5.8 million in Q2 2021 and bottomed at $4.9 million in Q4 2021.
- Historically, Assets Average has averaged $5.4 million across 5 years, with a median of $5.4 million in 2024.
- Annual changes were most pronounced in 2021 — Assets Average dropped 16.51% — and 2023, when it climbed 9.27%.
- International Stem Cell's Assets Average stood at $4.9 million in 2021, then gained by 2.97% to $5.1 million in 2022, then grew by 8.39% to $5.5 million in 2023, then retreated by 6.15% to $5.2 million in 2024, then fell by 2.43% to $5.1 million in 2025.
- Business Quant data shows ISCO's Assets Average at $5.1 million in Q4 2025, $5.4 million in Q3 2025, and $5.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 4.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.94 Mn |
| Dec 31, 2025 | 5.05 Mn |
| Sep 30, 2025 | 5.41 Mn |
| Jun 30, 2025 | 5.59 Mn |
| Mar 31, 2025 | 5.40 Mn |
| Dec 31, 2024 | 5.18 Mn |
| Sep 30, 2024 | 5.39 Mn |
| Jun 30, 2024 | 5.48 Mn |
| Mar 31, 2024 | 5.38 Mn |
| Dec 31, 2023 | 5.52 Mn |
| Sep 30, 2023 | 5.71 Mn |
| Jun 30, 2023 | 5.56 Mn |
| Mar 31, 2023 | 5.24 Mn |
| Dec 31, 2022 | 5.09 Mn |
| Sep 30, 2022 | 5.23 Mn |
| Jun 30, 2022 | 5.46 Mn |
| Mar 31, 2022 | 5.22 Mn |
| Dec 31, 2021 | 4.94 Mn |
| Sep 30, 2021 | 5.27 Mn |
| Jun 30, 2021 | 5.82 Mn |